HR Execs on the Move

Skyhawk Therapeutics

www.skyhawktx.com

 
Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
MaryKate Flaherty
VP of Finance Profile
Bill Haney
Co Founder and Chief Executive Officer Profile

Similar Companies

Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Edifice Health

Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health.

Immunocellular Therapeutics (Fka: Optical Molecular Imaging Inc)

Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

STEMCELL Technologies

STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.

Alto Neuroscience

Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Our artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.